Clinical trial
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial…
NCT00314678 · John P. Fruehauf, Other · Completed
Key facts
| NCT number | NCT00314678 |
|---|---|
| Title | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer |
| Official title | Cisplatin Induction Followed by Paclitaxel Consolidation for the Treatment of Stage III and IV Epithelial Ovarian Cancer and Primary Peritoneal Cancer With In Vitro Correlates of Response |
| Lead sponsor | John P. Fruehauf, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epithelial Ovarian Cancer, Primary Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Topotecan, Cisplatin, Paclitaxel |
| Enrollment | 40 |
| Start date | Sep 1, 2005 |
| Completion | Apr 1, 2007 |
| First posted | Apr 14, 2006 |
| Last update posted | Dec 8, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: